Drugs / autologous dendritic cell-tumor fusion vaccine
autologous dendritic cell-tumor fusion vaccine
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT01239875 | Nov 2010 → Nov 2015 | MALT lymphoma, Waldenstrom macroglobulinemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, grade III lymphomatoid granulomatosis +6 | Mayo Clinic | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00085397 | Mar 2004 → ? | cutaneous melanoma | Dana-Farber Cancer Institute | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | autologous dendritic cell-tumor fusion vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01239875 ↗ |
| Modality | Vaccine | “autologous dendritic cell-tumor fusion vaccine” NCT00085397 ↗ |
| Route | Subcutaneous | “Given subcutaneously” NCT00085397 ↗ |